Akero's EFX Shows Significant Fibrosis Reversal In MASH Cirrhosis At 96 Weeks
(RTTNews) - Akero Therapeutics (AKRO) unveiled new data from its Phase 2b SYMMETRY trial highlighting the potential of efruxifermin - EFX to reverse fibrosis in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis or MASH.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
